52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
For example, a 90-day study using a cysteine-rich whey protein (a glutathione precursor) improved adaptive behavior scores in preschoolers with ASD
Regarding collateral effects, the most commonly reported were gastrointestinal-related (diarrhea, nausea, vomiting, constipation) mainly occurring during the dose escalation period
Contact your doctor if you experience: Severe or persistent nausea and vomiting Severe stomach pain (especially in the upper abdomen) or signs of pancreatitis Swelling of the face, lips, or throat (possible allergic reaction) Unusually fast heart rate or dizziness Such considerations underscore how semaglutide isnt a magic fix
Although preclinical data show promise (Loftis et al., 2013), their clinical applicability remains unclear owing to challenges, such as immune response variability and limited human trials
